EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study

Jianian Lai, Song Guan, Yu Wang, Qingyu Wang, Meng Yan, Kai Ren, Jun Wang, Nan Bi, Lujun Zhao

Frontiers in Immunology · 28.04.2026 · 17

DOI: 10.3389/fimmu.2026.1744239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Frontiers in Immunology, online erschienen am 28.04.2026. Verfasst von Jianian Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical Uni…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Consolidation Chemotherapy, Immunotherapy, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The purpose of this study was to evaluate the effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer (NSCLC) who received induction chemoimmunotherapy before chemoradiotherapy (CRT). Materials and methods Patients with stage III NSCLC who received induction chemoimmunotherapy before CRT with or without consolidation immunotherapy at 4 hospitals between February 2018 and December 2022 were retrospectively analyzed. The patients were divided into two groups on the basis of whether they received consolidation immunotherapy (Ind+Con group) or not (Ind group). Progression-free survival (PFS) and overall survival (OS) were assessed from the initiation of treatment and were estimated using the Kaplan–Meier method. One-to-one propensity score matching (PSM) was used to further minimize confounding effects.

Results

A total of 196 eligible patients were enrolled, with 124 (63.3%) in the Ind group and 72 (36.7%) in the Ind+Con group. The median follow-up was 24.6 months, and the median PFS and OS for the whole cohort were 24.8 months and 46.0 months, respectively. The median PFS was 25.5 months in the Ind group vs. 24.0 months in the Ind+Con group, with 2-year PFS rates of 52.2% vs. 47.7% (P = 0.472). The median OS was 46.0 months in the Ind group vs. not reached (NR) in the Ind+Con group, with 2-year OS rates of 78.0% vs. 83.8% (P = 0.578). After 1:1 PSM, the median PFS was 30.2 months vs. 24.0 months, with 2-year PFS rates of 55.4% vs. 47.7% (P = 0.261). The median OS was 46.0 months vs. NR, with 2-year OS rates of 80.8% vs. 83.8% (P = 0.960).

Conclusion

The effect of consolidation immunotherapy on patients with stage III NSCLC who receive induction chemoimmunotherapy before CRT needs to be further studied.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungConsolidation ChemotherapyImmunotherapyLung NeoplasmsAgedFemaleHumansMaleMiddle AgedChemoradiotherapyInduction ChemotherapyNeoplasm StagingRetrospective Studies

Stichwörter der Autor:innen

chemoradiotherapyconsolidation immunotherapyinduction chemoimmunotherapynon-small cell lung cancerprognosis

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center…
  • Department of Radiation Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
  • Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Hebei Clinical Research Center for Radiation Oncology, Shijiazhuang, China.

Zitieren

APA

Lai, J., Guan, S., Wang, Y., Wang, Q., Yan, M., Ren, K., Wang, J., Bi, N., & Zhao, L. (2026). The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1744239

Vancouver

Lai J, Guan S, Wang Y, Wang Q, Yan M, Ren K, et al. The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1744239

BibTeX
@article{Lai2026,
  author = {Lai, Jianian and Guan, Song and Wang, Yu and Wang, Qingyu and Yan, Meng and Ren, Kai and Wang, Jun and Bi, Nan and Zhao, Lujun},
  title = {The effect of consolidation immunotherapy on patients with stage III non-small cell lung cancer who received induction chemoimmunotherapy: a multicenter retrospective study},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1744239}
}
Kostenlos starten →